title: Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy?
source: Yahoo
date: 2025-10-12
url: https://finnhub.io/api/news?id=ee5917ba68769760214637993ba80b18b0fe5be6610bc69a3b0cdebe2cc11fcb
Zymeworks Inc. recently appointed Adam Schayowitz, Ph.D., MBA, as Acting Chief Development Officer to accelerate its pipeline and partnership integration, leveraging his nearly 20 years of oncology drug development experience. Dr. Schayowitz’s background in leading global development programs at Pfizer and Tesaro positions Zymeworks to potentially strengthen both its R&D execution and collaborative ventures in the oncology space. We'll examine how Dr. Schayowitz's leadership experience could...
